TY - JOUR
T1 - Extradomain-B fibronectin-targeted dextran-based chemical exchange saturation transfer magnetic resonance imaging probe for detecting pancreatic cancer
AU - Han, Zheng
AU - Zhang, Shuixing
AU - Fujiwara, Kenji
AU - Zhang, Jia
AU - Li, Yuguo
AU - Liu, Jing
AU - Van Zijl, Peter C.M.
AU - Lu, Zheng Rong
AU - Zheng, Lei
AU - Liu, Guanshu
N1 - Funding Information:
This work was supported by NIH grants P41EB024495, R01EB015032, R01CA211087, and R21CA215860.
Publisher Copyright:
© 2019 American Chemical Society.
PY - 2019/5/15
Y1 - 2019/5/15
N2 - A dextran-peptide conjugate was developed for magnetic resonance (MR) molecular imaging of pancreatic ductal adenocarcinoma (PDAC) through its overexpressed microenvironment biomarker, extradomain-B fibronectin (EDB-FN). This new agent consists of diamagnetic and biocompatible dextran and a targeting peptide. Dextrans can be directly detected by chemical exchange saturation transfer magnetic resonance imaging (CEST MRI) without the need for radionuclide or metallic labeling. In addition, large molecular weight dextran, dextran 10 (MW ∼10 kDa), provides an approximately 50 times higher sensitivity per molecule than a single glucose unit. The potential of this highly biocompatible diamagnetic probe is demonstrated in a murine syngeneic allograft PDAC tumor model. The biocompatibility and sensitivity of this new agent clearly show potential for a path to clinical translation.
AB - A dextran-peptide conjugate was developed for magnetic resonance (MR) molecular imaging of pancreatic ductal adenocarcinoma (PDAC) through its overexpressed microenvironment biomarker, extradomain-B fibronectin (EDB-FN). This new agent consists of diamagnetic and biocompatible dextran and a targeting peptide. Dextrans can be directly detected by chemical exchange saturation transfer magnetic resonance imaging (CEST MRI) without the need for radionuclide or metallic labeling. In addition, large molecular weight dextran, dextran 10 (MW ∼10 kDa), provides an approximately 50 times higher sensitivity per molecule than a single glucose unit. The potential of this highly biocompatible diamagnetic probe is demonstrated in a murine syngeneic allograft PDAC tumor model. The biocompatibility and sensitivity of this new agent clearly show potential for a path to clinical translation.
UR - http://www.scopus.com/inward/record.url?scp=85064992402&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064992402&partnerID=8YFLogxK
U2 - 10.1021/acs.bioconjchem.9b00161
DO - 10.1021/acs.bioconjchem.9b00161
M3 - Article
C2 - 30938983
AN - SCOPUS:85064992402
SN - 1043-1802
VL - 30
SP - 1425
EP - 1433
JO - Bioconjugate Chemistry
JF - Bioconjugate Chemistry
IS - 5
ER -